Edwards Lifesciences (EW) Cash & Equivalents (2009 - 2026)

Edwards Lifesciences' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $2.4 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 22.13% year-over-year to $2.4 billion; the TTM figure through Mar 2026 stood at $2.4 billion (down 22.13% YoY), while the FY2025 annual figure was $2.9 billion, down 3.52% from the prior year.
• Cash & Equivalents was $2.4 billion for Q1 2026 at Edwards Lifesciences, down from $2.9 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $3.7 billion in Q3 2024 to a low of $761.5 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $1.9 billion across 5 years, with a median of $1.4 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents soared 168.94% in 2024, then decreased 26.95% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $761.5 million in 2022, then soared by 48.69% to $1.1 billion in 2023, then surged by 168.94% to $3.0 billion in 2024, then decreased by 3.52% to $2.9 billion in 2025, then dropped by 16.76% to $2.4 billion in 2026.
• The last three Cash & Equivalents figures came in at $2.4 billion (Q1 2026), $2.9 billion (Q4 2025), and $2.7 billion (Q3 2025), per Business Quant data.